Nature’s Powerful CBGVA Transforms to THCVa: Research Analysis

Exploring cannabis compounds, particularly Cannabigerolic acid (CBGA) and Cannabigerovarinic acid (CBGVA), offers intriguing insights into their potential therapeutic benefits. Both CBGA and CBGVA are precursors in the biosynthesis of other cannabinoids, playing pivotal roles in the cannabis plant's chemical transformations. However, despite their similarities, they present distinct properties and potential applications, highlighted by the synthesis processes and research findings discussed in various scholarly sources.

CBGA: The "Mother" of Cannabinoids

Biosynthesis: CBGA, naturally synthesized in Cannabis plants from olivetolic acid and geranyl pyrophosphate, serves as a precursor to major cannabinoids like THCA, CBDA, and CBCA through specific enzymatic reactions within the cannabis plant. Those cannabinoids create even more of a cascade of actions in the vast majority of cannabinoids from the Cannabis plant that many are already aware of.

Health Benefits: Research suggests CBGA possesses anti-inflammatory, antibacterial, and neuroprotective properties, offering potential therapeutic benefits without psychoactive effects. Suzuki et al. (2023) provide evidence of CBGA's efficacy in ameliorating inflammation and fibrosis in nephropathy, illustrating its potential in addressing renal diseases.

Conversion and Availability: CBGA is converted to CBG through decarboxylation (heat) or over time, explaining its reduced presence in mature cannabis plants. This conversion limits the direct application of CBGA but underscores its foundational role in cannabinoid synthesis.

CBGVA: A Promising yet Less Explored Cannabinoid

Biosynthesis: CBGVA is synthesized similarly to CBGA but involves olivetolic acid and another compound from the plant called divarinolic acid. It serves as a precursor to cannabinoids like CBCVA, CBDVA, CBGV, and THCVA, which then transform in the plant into more compounds like CBGa does with CBC, CBD, CBG, and THC through oxidization, heat, or time.

Research and Potential Benefits: Although research on CBGVA is not as extensive, initial studies indicate potential for treating epilepsy, acne, and inflammation. Anderson et al. (2021) highlight its divergent effects on seizures in mouse models of epilepsy, suggesting a basis for further investigation into its anti-epileptic properties.

Comparative Analysis

While CBGA and CBGVA are crucial for synthesizing various cannabinoids, their distinct biosynthetic pathways and the specific enzymes involved define their unique roles within the cannabis plant.

CBGA's role as a precursor to major cannabinoids has been well-established, offering significant therapeutic benefits, particularly in anti-inflammatory and neuroprotective domains.

On the other hand, CBGVA, with its potential in treating epilepsy and acne, represents a burgeoning field of research that could unlock new therapeutic applications.

The ongoing research into CBGA and CBGVA emphasizes the complexity and potential of cannabis compounds. As our understanding deepens, the therapeutic applications of these cannabinoids could expand, offering new avenues for treating a wide range of conditions.

CBGVa creates THCVa

Tetrahydrocannabivarin (THCV) is a fascinating cannabinoid found in cannabis plants, known for its unique properties and effects, which distinguish it from THC, the most well-known psychoactive component of cannabis. The biosynthesis of THCV in cannabis plants involves a distinct pathway that leverages the plant's natural enzymatic processes.

Biosynthesis of THCV – A Varin Cannabinoid

Precursors and Enzymatic Reaction: THCV is synthesized in cannabis plants through a process similar to that of THC but with a critical difference in the precursor molecule involved. The process starts with the precursor cannabigerovarinic acid (CBGVA), which is analogous to cannabigerolic acid (CBGA), the precursor for most other cannabinoids, including THC, CBG, and CBD.

As we have gone over, CBGVA gets synthesized from geranyl pyrophosphate (GPP) and divarinolic acid (a variant of olivetolic acid used in THC biosynthesis) under the action of the enzyme CBGVA synthase, making Varin cannabinoids quite different than those that come from CBGa.

Conversion to THCVA: CBGVA converts into tetrahydrocannabivarin carboxylic acid (THCVA) by the enzyme THCVA synthase. This step is parallel to the conversion of CBGA into THCA (tetrahydrocannabinolic acid), the direct precursor to THCV.

Decarboxylation to THCV: The final step in producing THCV is the decarboxylation of THCVA, which can occur through exposure to heat or UV light. During decarboxylation, the carboxyl group (-COOH) in THCVA gets removed, converting it into THCV. This step is crucial for activating THCV's psychoactive properties, similar to how THCA gets converted into THC.

Distinct Characteristics of THCV

Chemical Structure: THCV has a propyl side chain rather than the pentyl side chain found in THC. This slight difference in molecular structure significantly affects its pharmacological properties.

Psychoactive Properties: At low doses, THCV acts as a CB1 antagonist, and that potentially reduces the psychoactive effects of THC, which could make it helpful in mitigating some of THC's less desirable effects, such as anxiety. At higher doses, it will exhibit psychoactive effects similar to THC but with a shorter duration.

Therapeutic Potential: Preliminary research suggests THCV could have various therapeutic applications, including in weight loss (by suppressing appetite), diabetes (by regulating blood sugar levels), and Parkinson's disease (by providing neuroprotective effects).

The biosynthesis of THCV in cannabis plants is a complex process influenced by the plant's genetics, the specific enzymes present, and environmental factors.

As research into cannabis and its myriad compounds deepens, our understanding of cannabinoids like THCV will continue to grow, opening up new possibilities for their use in medical and recreational contexts.

© 2024 Mike Robinson, Founder Global Cannabinoid Researcher Center and Creator of ECS Balance Control, The Researcher OG

References:

Suzuki S, Fleig A, Penner R. CBGA ameliorates inflammation and fibrosis in nephropathy. Sci Rep. 2023;13(1):6341

Anderson LL, Heblinski M, Absalom NL, et al. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. Br J Pharmacol. 2021;178(24):4826-4841

Walsh KB, McKinney AE, Holmes AE. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Front Pharmacol. 2021 Nov 29;12:777804. doi: 10.3389/fphar.2021.777804. PMID: 34916950; PMCID: PMC8669157

Soler-Cedeno O, Xi ZX. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge. Cells. 2022 Oct 17;11(20):3262. doi: 10.3390/cells11203262. PMID: 36291128; PMCID: PMC9600259

Abioye A, Ayodele O, Marinkovic A, Patidar R, Akinwekomi A, Sanyaolu A. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. J Cannabis Res. 2020 Jan 31;2(1):6. doi: 10.1186/s42238-020-0016-7. PMID: 33526143; PMCID: PMC7819335